1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
Amgen: Strong growth company with a challenging future

Strong growth company with a challenging future: Amgen Industry Report

  • December 2015
  • 27 pages
  • ID: 3701917
In this report:
Neulasta and ENBREL contributed to over ##% of the total sales revenue in 2009, while all of other drugs accounted for the rest of the sales revenue.
EPOGEN is also the first ever $## bn drug in the biotechnology industry and Amgen's financial reports consistently show EPOGEN accounts for over ##% of the total sales revenue.


Table of Contents

Search Inside


Since it was founded in 1980, Amgen has established itself as a leading overall biotechnology company and built increasingly strong human therapeutics brands and also state of the art manufacturing facilities. This case study analyses the company's new financial performance, evaluates the strategies that have helped it become a overall leader, and explores what the outlook may hold.

Main elements and benefits

- Investigation of Amgen's success and An in-depth study of its rise to be one of the most innovative biotechnology companies in the globe.

- Parallel comparisons relating to R&D, stock market and financial performance to identify its strengths and weaknesses among its peers.

- Analysis of the challenges that Amgen faces both internally and externally.

- The case study also focuses on the R&D and acquisition strategy of the company.

Key Findings

- Since it was founded by William K. Bowes and associates in 1980, Amgen has grown into a $120.0B company in just 35 years, generating meaningful profit in the process. The company's impressive financial numbers have generated excellent share price performance, but the company does face a number of challenges.

- Amgen has not only enjoyed quick organic growth due to its excellent R&D, a number of valuable acquisitions have also been proven to be instrumental to its expansion relating to product portfolio and revenue over the years. This strategy remains a central part of the company's plans.

Main answers from this analysis

- How did Amgen become the world's leading Biotechnology company?

- What are the main challenges the company now faces?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017

  • $ 3500
  • Company report
  • December 2017
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017SummaryAccording to the recently published report ’Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017’; Integrin Alpha 7 (ITGA7) pipeline Target ...

CH Biotech R&D Co Ltd

CH Biotech R&D Co Ltd

  • $ 99
  • Company report
  • October 2017
  • by Wright Investors' Service

A textual analysis of the financial results for CH Biotech R&D Co Ltd compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses ...

Clariant – Shanghai Catalyst R&D Center – China - Project Profile

Clariant – Shanghai Catalyst R&D Center – China - Project Profile

  • $ 75
  • Company report
  • October 2017
  • by Timetric

Synopsis"Clariant – Shanghai Catalyst R&D Center – China - Project Profile" contains information on the scope of the project including project overview and location. The profile also details project ...


Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.